Clinical characteristics of 609 adults with recurring ALL
Characteristic . | No. patients . |
---|---|
Age at first diagnosis | |
15-19 y | 117 |
20-34 y | 236 |
35-49 y | 49 |
Older than 50 y | 74 |
Sex | |
Male | 382 |
Female | 227 |
WBC count at first diagnosis | |
Less than 10 × 109/L | 248 |
10–49 × 109/L | 178 |
More than 50 × 109/L | 181 |
Unknown | 2 |
Immunophenotype (44 unknown) | |
B precursor | 409 |
T-cell | 92 |
Mature B | 12 |
Null | 30 |
Mixed | 22 |
Unknown | 44 |
Ph status (56 unknown) | |
Positive | 120 |
Negative | 433 |
Risk group at first diagnosis (67 unknown) | |
Standard | 287 |
High | 135 |
Very high | 120 |
Unknown | 67 |
Initial treatment at first diagnosis* | |
CR1 | |
Chemotherapy | 440 |
Sibling allograft | 60 |
MUD | 17 |
Autograft | 80 |
Other | 5† |
Preremission‡ | |
Sibling allograft | 6 |
Autograft | 1 |
Time from diagnosis to relapse | |
Less than 1 y | 333 |
1-2 y | 160 |
More than 2 y | 116 |
Site of relapse, no. patients (8 unknown) | |
BM alone | 523 |
BM + CNS | 33 |
CNS alone | 22 |
Extramedullary | 23 |
Unknown | 8 |
Characteristic . | No. patients . |
---|---|
Age at first diagnosis | |
15-19 y | 117 |
20-34 y | 236 |
35-49 y | 49 |
Older than 50 y | 74 |
Sex | |
Male | 382 |
Female | 227 |
WBC count at first diagnosis | |
Less than 10 × 109/L | 248 |
10–49 × 109/L | 178 |
More than 50 × 109/L | 181 |
Unknown | 2 |
Immunophenotype (44 unknown) | |
B precursor | 409 |
T-cell | 92 |
Mature B | 12 |
Null | 30 |
Mixed | 22 |
Unknown | 44 |
Ph status (56 unknown) | |
Positive | 120 |
Negative | 433 |
Risk group at first diagnosis (67 unknown) | |
Standard | 287 |
High | 135 |
Very high | 120 |
Unknown | 67 |
Initial treatment at first diagnosis* | |
CR1 | |
Chemotherapy | 440 |
Sibling allograft | 60 |
MUD | 17 |
Autograft | 80 |
Other | 5† |
Preremission‡ | |
Sibling allograft | 6 |
Autograft | 1 |
Time from diagnosis to relapse | |
Less than 1 y | 333 |
1-2 y | 160 |
More than 2 y | 116 |
Site of relapse, no. patients (8 unknown) | |
BM alone | 523 |
BM + CNS | 33 |
CNS alone | 22 |
Extramedullary | 23 |
Unknown | 8 |
One BMT on unknown date.
Other indicates one reduced-intensity sibling allogeneic HSCT, one reduced-intensity MUD allogeneic HSCT, one reduced-intensity haploidentical HSCT, one fully conditioned haploidentical HSCT, and one unknown type.
Preremission indicates HSCT performed in absence of achieving CR1.